Literature DB >> 18297526

Neutropenic fever and severe sepsis in adult acute myeloid leukemia (AML) patients receiving intensive chemotherapy: Causes and consequences.

Sari Hämäläinen1, Taru Kuittinen, Irma Matinlauri, Tapio Nousiainen, Irma Koivula, Esa Jantunen.   

Abstract

The objective of this study was to evaluate etiology and consequences of neutropenic fever in AML patients. Two hundred and ninety neutropenic periods following chemotherapy in 84 AML patients were retrospectively evaluated. Neutropenic fever was found in 280 periods (97%). Severe sepsis developed in 35 occasions (13%) and 9 patients (11%) died due to severe sepsis. In 165 episodes with neutropenic fever (59%), the potential causative organism was found in blood cultures. Gram-negative bacteria were more commonly found in patients who developed severe sepsis (40% vs. 23%, p = 0.03). CRP after 2 - 3 days from start with fever was higher in patients with severe sepsis (190 mg/L vs. 96 mg/L, p < 0.001) but the rise in CRP rather coincided than preceded with the development of severe sepsis. Severe sepsis is associated with significant mortality in AML patients. Earlier methods than CRP are needed to predict development of severe sepsis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18297526     DOI: 10.1080/10428190701809172

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  17 in total

1.  Prognostic factors for intensive care unit admission, intensive care outcome, and post-intensive care survival in patients with de novo acute myeloid leukemia: a single center experience.

Authors:  Peter Schellongowski; Thomas Staudinger; Michael Kundi; Klaus Laczika; Gottfried J Locker; Andja Bojic; Oliver Robak; Valentin Fuhrmann; Ulrich Jäger; Peter Valent; Wolfgang R Sperr
Journal:  Haematologica       Date:  2010-11-11       Impact factor: 9.941

2.  High pentraxin 3 level predicts septic shock and bacteremia at the onset of febrile neutropenia after intensive chemotherapy of hematologic patients.

Authors:  Matti Vänskä; Irma Koivula; Sari Hämäläinen; Kari Pulkki; Tapio Nousiainen; Esa Jantunen; Auni Juutilainen
Journal:  Haematologica       Date:  2011-09       Impact factor: 9.941

3.  Life-threatening and fatal infections in children with acute myeloid leukemia: a report from the Children's Oncology Group.

Authors:  Lillian Sung; Allen Buxton; Alan Gamis; William G Woods; Todd A Alonzo
Journal:  J Pediatr Hematol Oncol       Date:  2012-01       Impact factor: 1.289

4.  Polymorphisms of Toll-like receptors (TLR2 and TLR4) are associated with the risk of infectious complications in acute myeloid leukemia.

Authors:  U Schnetzke; B Spies-Weisshart; O Yomade; M Fischer; T Rachow; K Schrenk; A Glaser; M von Lilienfeld-Toal; A Hochhaus; S Scholl
Journal:  Genes Immun       Date:  2014-11-27       Impact factor: 2.676

5.  Predictive factors associated with induction-related death in acute myeloid leukemia in a resource-constrained setting.

Authors:  Fernanda Rodrigues Mendes; Wellington Fernandes da Silva; Raphael da Costa Bandeira de Melo; Douglas Rafaele Almeida Silveira; Elvira Deolinda Rodrigues Pereira Velloso; Vanderson Rocha; Eduardo Magalhaes Rego
Journal:  Ann Hematol       Date:  2021-10-21       Impact factor: 3.673

Review 6.  Concise review: next-generation cell therapies to prevent infections in neutropenic patients.

Authors:  Marion E G Brunck; Lars K Nielsen
Journal:  Stem Cells Transl Med       Date:  2014-03-05       Impact factor: 6.940

7.  Measuring Aging and Identifying Aging Phenotypes in Cancer Survivors.

Authors:  Jennifer L Guida; Tim A Ahles; Daniel Belsky; Judith Campisi; Harvey Jay Cohen; James DeGregori; Rebecca Fuldner; Luigi Ferrucci; Lisa Gallicchio; Leonid Gavrilov; Natalia Gavrilova; Paige A Green; Chamelli Jhappan; Ronald Kohanski; Kevin Krull; Jeanne Mandelblatt; Kirsten K Ness; Ann O'Mara; Nathan Price; Jennifer Schrack; Stephanie Studenski; Olga Theou; Russell P Tracy; Arti Hurria
Journal:  J Natl Cancer Inst       Date:  2019-12-01       Impact factor: 13.506

8.  Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.

Authors:  Eytan M Stein; Courtney D DiNardo; Daniel A Pollyea; Amir T Fathi; Gail J Roboz; Jessica K Altman; Richard M Stone; Daniel J DeAngelo; Ross L Levine; Ian W Flinn; Hagop M Kantarjian; Robert Collins; Manish R Patel; Arthur E Frankel; Anthony Stein; Mikkael A Sekeres; Ronan T Swords; Bruno C Medeiros; Christophe Willekens; Paresh Vyas; Alessandra Tosolini; Qiang Xu; Robert D Knight; Katharine E Yen; Sam Agresta; Stephane de Botton; Martin S Tallman
Journal:  Blood       Date:  2017-06-06       Impact factor: 25.476

Review 9.  Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO).

Authors:  Olaf Penack; Carolin Becker; Dieter Buchheidt; Maximilian Christopeit; Michael Kiehl; Marie von Lilienfeld-Toal; Marcus Hentrich; Marc Reinwald; Hans Salwender; Enrico Schalk; Martin Schmidt-Hieber; Thomas Weber; Helmut Ostermann
Journal:  Ann Hematol       Date:  2014-04-29       Impact factor: 3.673

10.  Metagenomic analysis of bloodstream infections in patients with acute leukemia and therapy-induced neutropenia.

Authors:  P Gyarmati; C Kjellander; C Aust; Y Song; L Öhrmalm; C G Giske
Journal:  Sci Rep       Date:  2016-03-21       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.